高雄榮民總醫院崇德病房（2013）．緩和醫療與安寧住院療護簡介．取自http://www.vghks.gov.tw/fm/hospice/intro.htm
陳麗系(2007)．成人健康護理之心理層面．於于博芮等編著，成人內外科護理(四版，232-233頁)．台北：華杏。
台北、台中、高雄榮民總醫院高齡醫學團隊（2010）．飲食照護篇．於陳亮恭編著，圖解居家長期照護全書（初版，286-329頁）．台北︰原水文化。
衛生署傳染病防治諮詢會預防接種組流感疫苗工作小組(2013)．流感疫苗之接種建議．疫苗專欄．29(10)，145-148。
疾病管制局(時間不詳)．流感疫苗接種須知．2012年11月14日 取自http://www.cdc.gov.tw/vaccinationtheme.aspx?treeid=d78de698c2e70a89&nowtreeid=aae079470c4424c3。
疾病管制局(時間不詳)．流感疫苗接種注意事項．2012年11月14日 取自http://www.cdc.gov.tw/vaccinationtheme.aspx?treeid=d78de698c2e70a89&nowtreeid=aae079470c4424c3。
慈濟健康網(時間不詳)．流感疫苗的注意事項．2012年11月14日 取自http://www.tzuchi.com.tw/tzuchi/Health_ContentHealth/Default.aspx?Action=ViewDetail&ContentType=1&ContentModule=0&IdentityID=84。
Hatano S, Strasser T. World Health Organization 1975. Primary pulmonary hypertension. Geneva: WHO; 1975.
D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur Respir J 2009;doi: 10.1183/09031936.00145608
Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz R, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55–S56.
Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803–815.
Gabbay E, Yeow W, Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary Hhypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Resp Crit Care Med 2007; 175:A713.
Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine S, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43–S54.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903.
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 Feb;25(2):244-9.
Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, Wlodarczyk J, Dalton B. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension. Intern Med J. 2011 Mar;41(3):227-34. doi: 10.1111/j.1445-5994.2009.02139.x.
Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010–3019.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005;353:2148–2157.
Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417–2422.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302.
McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.
Michael Rodgers, M.D: Primary Raynaud's Phenomenon, N Engl J Med 2013; 368:1344
Fredrick MW: Clinical manifestations and diagnosis of Raynaud’s phenomenon. UpToDate, 2011.
Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S
陳資濤蘇健吳健樑. 肺動脈高壓的治療. 內科學誌2009；20：19-29
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164-72. Epub 2010 Jun 28.
Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients withpulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 Feb;25(2):244-9. Erratum in: Eur Respir J. 2005 May;25(5):942.
Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, Torres F, Chin KM. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. Card Fail. 2010 Feb;16(2):121-7. Epub 2009 Nov 20.
Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ; ARIES Study Group.
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension .J Am Coll Cardiol. 2009 Nov 17;54(21):1971-81. Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? BMC Cardiovasc Disord. 2010 Feb 22;10:9.
Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: S35-S62.
Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006 Jun;129(6):1636-43.
Olschewski H, Hoeper MM, Behr J, Ewert R, Meyer A, Borst MM, Winkler J, Pfeifer M, Wilkens H, Ghofrani HA, Nikkho S, Seeger W. Long-term therapy with inhaled iloprost in patients with pulmonary hypertensionRespir Med. 2010 May;104(5):731-40. Epub 2010 Feb 11..
Siobal MS. Pulmonary vasodilators. Respir Care. 2007 Jul; 52(7):885-99.
Yanagisawa R, Kataoka M, Taguchi H, Kawakami T, Tamura Y ,Fukuda K ,Yoshino H ,Satoh T. Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension.Circ J. 2012 Apr 25;76(5):1245-52. Epub 2012 Feb 14.
Galie, N, Ghofrani, HA, Torbicki, A, et al.Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-57,
Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000; 188: 1497-500.64
Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001; 120: 1547-55.
Zamanian RT, Haddad F, Doyle RL, et al. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007; 35: 2037-50.
Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 655-74.
Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84: 682-6.
James R Runo, James E Loyd. Primary pulmonary hypertension. Lancet 2003;361:1533-44.
Barst, Robyn J, McGoon, M, Torbicki, A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;354:1425-36.
Simonneau,G, Galie, N, Rubin, LJ, et al. Clinical classification of pulmomory hypertension. J Am Coll Cardiol 2004;43:10S.
RuBin, L J. Diagonosis and management of pulmonary arterial hypertension; ACCP evidenceb asedclinical practice guidelines. Chest 2004;126:7S-10S.
Macchia, A, Marchioli, R, Marfisi, R, et al. A metaanalysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47.
Rich, S. The value of approved therapies for pulmonary arterial hypertension. Am Heart J 2007; 153:889.
Badesch, DB, Abman, SH, Simonneau, G, et al. Medical therapy for pulmonary arterial hypertension; updated ACCP evidence-based clinical practice guideline. Chest 2007; 131:1917- 1928.
Galie, N, Ghofrani, HA, Torbicki, A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-57.
http://www.24drs.com/professional/list/content.asp?x_classno=0&x_idno=5253&x_chkdelpoint=Y
Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013;369:809-18.
Proceedings of the 4th world symposium on pulmonary hypertension. J Am CollCardiol 2009;54(1 Suppl).
Bolli MH et al. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist. J Med Chem. 2012; 55:7849-61.
Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012). Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells. PLOS ONE 7(10)：e47662.
Michael Rodgers, M.D: Primary Raynaud's Phenomenon, N Engl J Med 2013; 368:1344
Fredrick MW: Clinical manifestations and diagnosis of Raynaud’s phenomenon. UpToDate, 2011.
Iglarz M et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J PharmacolExpTher. 2008;327(3):736-45.
Sidharta PN et al. Macitentan：Entry-into-humans study with a new endothelin receptor antagonist. Eur J ClinPharmacol. 2011;67(10):977-84
Bruderer S et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012 Sep;42(9):901-10
Bruderer S et al. Effect of cyclosporine A and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012;14(1):68-78.
Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension：the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest 2012;142:448-56.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group.Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med.2013 Jul 25;369(4):330-40.
Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C;CHEST-1 Study Group .Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013 Jul 25;369(4):319-29